Over 60% of U.S. adults aged 30-79 without diagnosed heart disease "have an indication for statin therapy under the 2026 ACC/AHA dyslipidemia guideline."
The greatest total expansion of eligibility resulted from considering the risk of a heart attack over the next 30 years in adults aged <60 years.
